Background/Aims: National Plans for Rare Diseases (RDs) are the common denominator of current public health policy concerns on RDs across the EU. With the aim of a better distribution of the available resources, they conjugate the European objective that aims at ensuring that patients with RDs have access to high-quality care - including diagnostics, treatment and rehabilitation - with the national priorities of selecting specific measures for adoption and implementation. Methods: The European Project for Rare Diseases National Plans Development (EUROPLAN, www.europlanproject.eu) is cofunded by the EU Commission (DG-SANCO) and is coordinated by the Italian National Center for Rare Diseases of the Istituto Superiore di Sanità (ISS). The EUROPLAN goal is to promote the implementation of National Plans or Strategies to tackle RDs and share relevant experiences within countries, linking national efforts, through a common strategy at a European level. In order to fulfill these objectives, EUROPLAN involved health authorities, clinicians, scientists, the European Organisation for Rare Diseases (EURORDIS), and many other patient groups as associated and collaborating partners from several European countries. Results: The project was launched in 2008 and foresaw 2 implementation phases: phase 1 (2008-2011) to build the consensus definition of operational tools (recommendations and indicators), and the ongoing phase 2 (2012-2015), mainly aimed at capacity building with the proactive involvement of multilevel stakeholders. EUROPLAN is facilitating and accelerating the implementation of National Plans in almost all EU and several non-EU Countries. Conclusions: EUROPLAN is a European and an international process more than a project, and it could be defined as a ‘litmus test' demonstrating how the collaboration between institutions and patients' associations can accelerate the process of awareness and development of policies and actions.

1.
Second Programme of Community Action in the Field of Health 2008-2013. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:301:0003:0013:EN:PDF (accessed June 26, 2013).
2.
Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges. 2008. http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf (accessed June 26, 2013).
3.
EU Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official journal of the European Union (2009/C 151/02). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF (accessed June 26, 2013).
4.
Report on Initiatives and Incentives in the Field of Rare Diseases. 2009. http://www.europlanproject.eu/_newsite_986989/Resources/docs/2008-2011_1.EUCERDReport.pdf (accessed June 26, 2013).
5.
Recommendations for the development of National Plans for Rare Diseases - Guidance document. http://www.europlanproject.eu/_newsite_986989/Resources/docs/2008-2011_2.EUROPLANRecommendations.pdf (accessed June 26, 2013).
6.
Report on indicators for monitoring the implementation and evaluating the impact of National Plan or Strategy for rare diseases. http://www.europlanproject.eu/_newsite_986989/Resources/docs/2008-2011_3.EUROPLANIndicators.pdf (accessed June 26, 2013).
7.
Final Report on key results of the 15 EUROPLAN National Conferences. http://www.europlanproject.eu/_newsite_986989/Resources/docs/2008-2011_4.EUROPLAN%20FINALREPORT.pdf (accessed June 26, 2013).
8.
EUCERD Recommendations on Core Indicators for National Plans/Strategies for Rare Diseases. http://www.europlanproject.eu/_newsite_986989/Resources/docs/EUCERD_Recommendations_Indicators_adopted.pdf (accessed June 26, 2013).
9.
Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF (accessed June 26, 2013).
10.
EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in MS. 2011. http://www.eucerd.eu/?post_type=document&p=1224 (accessed June 26, 2013).
11.
EUCERD Recommendations on European Reference Networks for Rare Diseases. 2013. http://www.eucerd.eu/?post_type=document&p=2207 (accessed June 26, 2013).
12.
Recommendations of the EUCERD to the European Commission and the Member States on Improving Informed Decisions Based on the Clinical Added Value of Orphan Medicinal Products (CAVOMP) Information Flow. 2012. http://www.eucerd.eu/?post_type=document&p=1446 (accessed June 26, 2013).
13.
EUCERD Recommendations on Rare Disease Patient Registration and Data Collection. 2013. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf (accessed June 26, 2013).
14.
EUCERD Recommendations on Core Indicators for Rare Disease National Plans/ Strategies. 2013. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_Indicators_adopted.pdf (accessed June 26, 2013).
15.
Taruscio D, Vittozzi L, Stefanov R: National plans and strategies on rare diseases in Europe. Adv Exp Med Biol 2010;686:475-491.
16.
Baker LC, Hopkins D, Dixon R, Rideout J, Geppert J: Do health plans influence quality of care? Int J Qual Health Care 2004;16:19-30.
17.
Baker LC, Hopkins DSP: The contribution of health plans and provider organizations to variations in measured plan quality. Int J Qual Health Care 2010;22:210-218.
18.
Birt CA, Gunning-Schepers L, Hayes A, Joyce L: How should public health policy be developed? A case study in European public health. J Public Health Med 1997;19:262-267.
19.
Dirksen CD, Utens CM, Joore MA, van Barneveld TA, Boer B, Dreesens DHH, van Laarhoven H, Smit C, Stiggelbout AM, van der Weijden T: Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study. Implement Sci 2013;8:64.
20.
Van der Weijden T, Légaré F, Boivin A, Burgers JS, van Veenendaal H, Stiggelbout AM, Faber M, Elwyn G: How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol. Implement Sci 2010;5:10.
21.
Klazinga N, Stronks K, Delnoij D, Verhoeff A: Indicators without a cause. Reflections on the development and use of indicators in health care from a public health perspective. Int J Qual Health Care 2001;13:433-438.
22.
Etches V, Frank J, Di Ruggiero E, Manuel D: Measuring population health: a review of indicators. Annu Rev Public Health 2006;27:29-55.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.